Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 23;11(4):327-334.
doi: 10.1055/s-0041-1726091. eCollection 2022 Dec.

Evaluation of an Enteral Clonidine Taper following Prolonged Dexmedetomidine Exposure in Critically Ill Children

Mara F Crabtree  1 , Cheryl L Sargel  1 , Colleen P Cloyd  1 , Joseph D Tobias  2 , Mahmoud Abdel-Rasoul  3 , R Zachary Thompson  1
Affiliations

Evaluation of an Enteral Clonidine Taper following Prolonged Dexmedetomidine Exposure in Critically Ill Children

Mara F Crabtree et al. J Pediatr Intensive Care. .

Abstract

The aim of the current study is to evaluate the use of an enteral clonidine transition for the prevention or management of dexmedetomidine withdrawal symptoms in critically ill children not exposed to other continuous infusion sedative agents. A retrospective, single-center study was conducted in patients ≤ 18 years of age admitted to the pediatric intensive care unit who received a continuous infusion of dexmedetomidine for ≥ 24 hours and who were prescribed enteral clonidine within 72 hours of dexmedetomidine discontinuation. Predefined withdrawal terminology was established to assess for hypertension, tachycardia, agitation, tremors, and decreased sleep. A total of 105 patients were included and received enteral clonidine for prevention or management of dexmedetomidine withdrawal symptoms, with 13 patients (12.4%) requiring a taper modification to manage withdrawal symptoms. The median duration of dexmedetomidine infusion was 120.5 hours (95.5, 143.5) and median peak infusion rate was 1 µg/kg/h (1, 1.2). A higher cumulative dexmedetomidine dose of 119.2 µg/kg (96.6, 154.9) and duration of 142.9 hours (122.6, 158.3) were noted in patients who required a taper modification. Risk factors for dexmedetomidine withdrawal such as dexmedetomidine duration and cumulative dose may help predict patients at the highest risk of withdrawal that would benefit from an enteral clonidine taper to prevent dexmedetomidine withdrawal symptoms. An enteral clonidine taper can be effective in the prevention and management of dexmedetomidine withdrawal symptoms.

Keywords: clonidine; dexmedetomidine; pediatric intensive care unit; taper; withdrawal.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
Flow diagram inclusion/exclusion.
See this image and copyright information in PMC

References

    1. Lake Forest, IL: Hospira, Inc.; 2016. Precedex (R) [package insert]
    1. Hsu Y W, Cortinez L I, Robertson K M. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004;101(05):1066–1076. - PubMed
    1. Weerink M AS, Struys M MRF, Hannivoort L N, Barends C RM, Absalom A R, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(08):893–913. - PMC - PubMed
    1. SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group . Riker R R, Shehabi Y, Bokesch P M. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(05):489–499. - PubMed
    1. Whalen L D, Di Gennaro J L, Irby G A, Yanay O, Zimmerman J J. Long-term dexmedetomidine use and safety profile among critically ill children and neonates. Pediatr Crit Care Med. 2014;15(08):706–714. - PubMed